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patients were analyzed to identify subgroups of patients regarding potential for DDI 
and antipsychotic treatment costs. RESULTS: Of 8221 schizophrenia patients identi-
ﬁ ed in the data base 28.2% had co-prescriptions with potential for DDI and were 
regarded as subgroup for well directed use of PER. The average antipsychotic costs/
quarter of these patients were €399.0/patient for atypicals; €276.5/patient for generic
and €613.2/patient for patent protected atypicals (incl. PER). The average treatment 
costs/quarter for PER were 551.0 EUR/patient. PER treatment of all patients treated 
with patent protected atypicals at risk for DDI would reduce the overall antipsychotic
expenditure for schizophrenia by 1.9%. PER treatment of all atypical patients 
with potential DDI would increase the schizophrenia antipsychotics budget by 
8.0%. CONCLUSIONS: The budgetary impact of well directed used PER is limited
by the share of schizophrenia patients with potential DDI. As PER is associated with 
10% lower treatment costs compared to patent protected atypicals, PER could reduce
costs if used instead of other patent protected atypicals. Reduced risk for DDI com-
plications with PER may lead to additional cost savings that are not captured in this 
analysis.
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OBJECTIVES: To investigate the costs of dementia in Hungary, analyzing the distribu-
tion of direct and indirect costs, considering also the costs of caregivers. On basis of 
prevalence estimations from previous dementia studies we extrapolated the mean cost
issues and estimated the burden of dementia for the population aged 50 in Hungary. 
METHODS: A cross-sectional study of 88 consecutive patients with dementia and
their caregivers was conducted in 2008 involving physicians and nurses of 3 GP and
1 outpatient practices. Resource Utilization in Dementia (RUD), Mini Mental State
Examination (MMSE), and the health related quality of life EuroQoL (EQ-5D) ques-
tionnaires were applied. Using 2007 prices we established the proportion of the main
cost-drivers and categorized cost-data by patients’ age and MMSE scores. RESULTS:
Patients (59% female) were involved with clinical characteristics of mean MMSE 16.7
(SD 7.24), EQ-5D 0.401 (SD 0.327.), 59% were female, mean age was 78 years (SD 
8.5). The average monthly direct costs per patient were 282 (SD 532) euros, mean
indirect costs were 53 (SD 187) euros/patient/month. Total costs by age-groups (total
sample, 65–74, 75–84 and 85 or more years) considering mental status (MMSE score 
level of 0–18, 19–24 and 25–30) within each were 176, 234, 108, 131 and 375, 588,
166, 67 and 418, 569, 262, 121 euros/patient/month, respectively. Dementia-related 
health services and indirect costs (income loss of caregivers) had the highest shares of 
the whole, 32%–32%for both. CONCLUSIONS: Costs of increase by age and severity
of the disease (measured by MMSE scores). At national level, in 2008 the estimated
direct costs of dementia were 255 million euros with 48 million euros indirect costs. 
Trends show a remarkable growth in the number of the demented patients. Therefore,
an increase of disease burden of dementia is expected in the future.
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OBJECTIVES: To compare, through cost-beneﬁ t analysis, a long-acting atypical anti-
psychotic (risperidone) with two second-generation oral antipsychotics (olanzapine
and clozapine) and a “typical” prolonged action antipsychotic (pipotiazine).
METHODS: We designed a decision tree that included only direct costs, from the 
third party payer perspective and a single year time frame. Main epidemiological
variables, obtained mostly from international literature and clinical trials, were adher-
ence, relapses with and without hospitalization, and side effects. Local costs were 
obtained from Colombian health insurers and providers. RESULTS: According to the
model, the use of long acting risperidone injection was associated with the lowest 
overall costs to the system (US$5169 per year) followed closely by clozapine (US$5221) 
whose long term metabolic effects were not included in the model. Either one of these
drugs would save around US$ 800 per year when compared with olanzapine
(US$6087), and more than US$1000 when compared with pipotiazine (US$6544), the 
least expensive of the group and currently the standard of care in most patient groups.
CONCLUSIONS: Despite their apparent higher costs, atypical antipsychotics can be 
cost saving through their reduction in relapses and hospitalizations. The economic
beneﬁ t, particularly with risperidone injection which had the lowest side effects, would
be added to the direct and indirect beneﬁ ts to the patients and their communities due 
mainly to relapse reduction.
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OBJECTIVES: Bipolar disorder has an associated economic burden due to its treat-
ment, including medication and hospitalization costs as well as costs associated with
treatment of comorbid medical conditions. This study compared health care costs in 
patients treated with a mood stabilizer and adjunctive aripiprazole versus adjunctive 
olanzapine, quetiapine, risperidone or ziprasidone. METHODS: A retrospective 
propensity score-matched cohort study was conducted in the LabRx integrated
claims database from January 2003 through December 2006. Patients aged 18–65 
years with bipolar disorder and 180 days of pre-index enrolment without atypical
antipsychotic therapy and 90 days post-index enrolment were eligible for inclusion.
Mood stabilizer therapy was initiated prior to index atypical prescription. Generalized
gamma regressions were used to compare the total health care costs of patients 
treated with adjunctive aripiprazole and patients treated with adjunctive olanzapine, 
quetiapine, risperidone or ziprasidone. RESULTS: After controlling for differences in 
baseline characteristics and pre-index cost, psychiatric costs and subtotal psychiatric 
and general medical cost were signiﬁ cantly higher for all adjunctive atypical antipsy-
chotics than adjunctive aripiprazole (p  0.001). There was no signiﬁ cant difference
in general medical costs between aripiprazole and ziprasidone, olanzapine, or quetiap-
ine. Aripiprazole medication costs were signiﬁ cantly higher than for quetiapine and 
risperidone (p  0.001) but not olanzapine or ziprasidone. Total health care costs
were signiﬁ cantly higher for ziprasidone, olanzapine, or risperidone (p  0.001) than 
aripiprazole but not for quetiapine. CONCLUSIONS: Adjunctive aripiprazole may 
have economic beneﬁ ts over other atypical antipsychotics in terms of lower psychiatric 
treatment costs of care than adjunctive olanzapine, quetiapine, risperidone or ziprasi-
done, and lower total health care costs than adjunctive olanzapine, risperidone or
ziprasidone.
PMH18
HEALTH CARE RESOURCE UTILIZATION ANALYSIS OF PRE/POST
LONG-ACTING RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA 
AND SCHIZOAFFECTIVE DISORDERS IN THREE REGIONAL PUBLIC 
HOSPITALS IN HONG KONG
Lee KK1, Lee EH2, Lee VWY1, Chung DW2
1The Chinese University of Hong Kong, Shatin, Hong Kong, 2The Chinese University of Hong
Kong, Hong Kong, China
OBJECTIVES: The objective of this study was to compare the health care utilization 
and associated cost in a group of schizophrenia and schizoaffective patients pre and 
post risperidone long-acting injection (RLA) treatment. METHODS: This was a ret-
rospective cost analysis study. Data was gathered solely from hospital records, which 
were reviewed for data pertaining to utilization of health care resources. The study
was performed from a public health care institute’s perspective. Patients studied were
from three public hospitals in Hong Kong. They were started on antipsychotic treat-
ment but later on switched to RLA therapy due to adverse effects, poor response or 
whatever reasons and remained on risperidone for a minimum of 12 months. The 
initial RLA administration date served as the index date. Study periods included 12-
month pre and 24-month post the index date and patients served as their own control.
Cost data collected included medications, laboratory procedures, other more sophis-
ticated investigational procedures (e.g. CT, MRI), regular and extra outpatient clinic 
visits, emergency room utilization, hospitalization, and other health services such as 
special counseling sessions. RESULTS: A total of 180 patients who received RLA
treatment were identiﬁ ed from 2 public general and 1 psychiatric hospitals in Hong 
Kong over the period of 2003–2006. The overall annual cost of treatment before and
after RLA injection was HKD80.5 million (USD10.3 million; 1USD  7.8HKD) and 
HKD26 million (USD3.34 million) respectively. The annual average cost per patient 
before and after RLA treatment was HKD447,300 (USD57,300) and HKD144,600 
(USD18,500) respectively. CONCLUSIONS: From the present group of patients 
assessed two years after initiation of RLA treatment, it appears that the treatment can 
potentially lead to substantial cost savings. The major cost driver appears to be hos-
pitalization due to either poor control or adverse effects of medications.
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OBJECTIVES: First-line treatment of MDD patients with a generic SSRI is often 
encouraged by managed care organizations. However, some patients may require 
second line therapy. This study evaluates the economic consequences associated with 
three options of second-line treatment: escitalopram, an SNRI (venlafaxine or dulox-
etine), or a generic SSRI. METHODS: Adult MDD patients treated with a generic 
SSRI were identiﬁ ed in the Ingenix Impact database (2003–2007) and included if they 
switched to escitalopram, an SNRI, or another generic SSRI. Urgent care utilization
during the 3-month follow-up was compared across these three study cohorts. Costs 
incurred during three months pre- vs. post-switching date were compared descriptively 
and using regression analyses adjusting for patient demographics, comorbidities, prior
resource use and length of therapy. RESULTS: The study identiﬁ ed 7,774 switchers 
to escitalopram, 10,505 to SNRIs, and 6,723 to a generic SSRI. Compared to escitalo-
pram switchers, patients who switched to an SNRI or a generic SSRI had an increased
adjusted risk of mental health-related urgent care utilization (OR  1.30 and 1.17 
respectively, both P  0.05). Patients who switched to escitalopram had a $402 reduc-
tion in medical costs (P  0.001) during the 3-month follow-up period compared to
